Editas Medicine, Inc. Inducement Stock Option AgreementInducement Stock Option Agreement • February 26th, 2020 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions.Letter Agreement • February 26th, 2020 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This letter agreement (“Letter Agreement”) is entered into as of the date provided above (the “Effective Date”) by and between, on the one hand, the President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, MA 02138 (“Harvard”) and The Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Main Street, Cambridge, MA 02142 (“Broad,” together with Harvard, the “Institutions” and each individually, an “Institution”) and, on the other hand, Editas Medicine, Inc., a Delaware corporation, with a principal office at 11 Hurley Street, Cambridge, MA 02141 (“Company”). Company and the Institutions are each referred to herein as a “Party” and together, the “Parties.”
EDITAS MEDICINE, INC. INDUCEMENT RESTRICTED STOCK UNIT AGREEMENTInducement Restricted Stock Unit Agreement • February 26th, 2020 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
LICENSE AGREEMENTLicense Agreement • February 26th, 2020 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of November 11, 2019 (the “Execution Date”) by and between Editas Medicine, Inc., a Delaware corporation, having its principal place of business at 11 Hurley St., Cambridge, MA 02141 corporation (“Editas”) and Juno Therapeutics, Inc., a Delaware corporation, having its principal place of business at 400 Dexter Avenue North, Suite 1200, Seattle, WA 98109 (“Juno”). Juno and Editas are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. SECOND AMENDED AND RESTATED...Collaboration and License Agreement • February 26th, 2020 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This SECOND AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of November 11, 2019 (the “Amendment Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having its principal place of business at 11 Hurley St., Cambridge, MA 02141 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having its principal place of business at 400 Dexter Avenue North, Suite 1200, Seattle, WA 98109 (“Juno”) and amends and restates (a) that certain Collaboration and License Agreement by and between Editas and Juno (the “Original Agreement”), dated as of May 26, 2015 (the “Original Effective Date”); and (b) that certain Amended and Restated Collaboration and License Agreement by and between Editas and Juno (the “First Amended and Restated Agreement”), dated as of May 3, 2018 (the “First Amended Effective Date”).
